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contraceptive as well as non-contraceptive beneﬁts. Lack of knowledge among women, dependence on the
provider for information, and provider bias for permanent contraception are cited as reasons for this reduced
uptake. Training of healthcare providers and increased patient awareness about the effectiveness of long-acting
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Unintended pregnancies remain a substantial global public health
issue despite considerable advances in contraceptive technologies. In
the 21st century, women have gained access to many contraceptive
options. However, the unmet need for contraception in low-resource
countries has been estimated at 222 million women who are not using
any contraceptive methods to delay or stop childbearing [1]. Numerous
reasons explain this, such as limited choice of methods available, limited
access to family planning services, fear or experience of adverse effects,
cultural or religious opposition, poor quality of available services, and
gender-based barriers. A basic right of all couples and individuals is to de-
cide freely and responsibly the number and spacing of their children and
to have the information, education, and means to do so.
2. Contraceptive prevalence
Contraceptive use and unmet need for family planning are key to
understanding how reproductive health can be improved. Globally, con-
traceptive prevalence amongmarried or in-union women of reproductive
age has increased from 55% in 1990 to 63% in 2011 [2]. In the lowest-
income countries, 36% ofmarried or in-unionwomen are using contracep-
tivemethods, while it is twice as high in high-income countries at 66% [3].
Female sterilization and intrauterine devices (IUDs) were the two most
commonmethods used in both 1990 and 2011 [3]. Method-speciﬁc prev-
alence has varied widely across regions since 1990, with femaleResearch Centre, Shanti Nagar,
fax: +91 141 2762091.
behalf of International Federation ofsterilization common in Asia, Latin America, and the Caribbean and
North America, and IUDs continuing to be important in Asia and Europe.
In countries where childbearing begins at a young age, the domi-
nance of female sterilization (estimated to be 65% in India [3]) indicates
a need for effective reversible methods that could help meet women’s
preference to delay the start of childbearing and to space birth. In
high-resource countries, one out of every four contraceptive users relied
on female sterilization or IUDs [3]. By contrast, in low-resource coun-
tries the methods with highest prevalence were female sterilization
(21%) and IUDs (15%), accounting for 57% of overall contraceptive use
[3]. Nine out of every 10 contraceptive users in the world rely on mod-
ern methods of contraception [3].
Table 1 shows that although the proportion ofwomenusingmodern
contraceptivemethods did not increase substantially between2003 and
2012, the number of users increased by 139 million over the same time
period, with average annual increases of 15million. Of this increase, 106
million is attributable to increased numbers of women, and 33 million
to growth in the proportion using modern methods.
Between 2003 and 2012, the total numbers of women using each type
of method increased, while the distribution by type of method showed in-
creasing use of long-acting reversible contraception (LARC), oral contracep-
tives, andbarriermethods, and falling trends inuseof sterilization and IUDs.3. Permanent methods
Sterilization has become the most popular method of contraception
[4], and more than two-thirds of all sterilization procedures worldwide
are performed for contraceptive purposes [5]. Around 190 million cou-
ples rely on tubal occlusion [6].Gynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
Table 1
Percentage distribution of women using modern contraceptives by type of method in
2003, 2008, and 2012.a
Region Year
2003 2008 2012
All low-income countries
PM 47 42 38
IUD 27 30 28
LARC 6 8 9
OCs 12 11 13
BM 7 10 13
Number (millions) of women
(aged 15–49 years)
1321 1448 1520
Number (millions) wanting
to avoid pregnancy (%)
716 (54%) 827 (57%) 867 (57%)
69 poorest countries
PM 49 48 45
IUD 14 11 12
LARC 12 14 16
OCs 16 16 16
BM 9 11 11
Higher-income countries
PM 46 38 33
IUD 34 41 38
LARC 4 4 4
OCs 10 8 1
BM 6 9 14
Abbreviations: PM, permanent method; IUD, intrauterine device; LARC, long-acting re-
versible contraception (injectables or implants); OC, oral contraceptives; BM, barrier
methods.
a Source: Darroch and Singh [42].
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Globally, female sterilization is used by 19% of women aged 15–49
years who are married or in union [3]. It is the most prevalent method
in Latin America and the Caribbean (26%), with the highest prevalence
found in the Dominican Republic (47%). In Columbia, Costa Rica, El
Salvador, and Puerto Rico, prevalence ranges between 30% and 40%,
whereas it is over 25% in Brazil, 27% in China, and 36% in India [3]. De-
spite being safer, simpler, and more effective than female sterilization,
male sterilization lags behind. The number of female sterilization proce-
dures exceeds the number of male procedures by 5:1 [7]. Worldwide,
2.4% of men of reproductive age have had a vasectomy.
Female sterilization is a safe and effectivemethod that involves occlu-
sion of the fallopian tubes by either an abdominal or transcervical route.
Using the abdominal route, the fallopian tubes can be accessed either by
mini-laparotomy or laparoscopically. This procedure can be performed
at the time of delivery or shortly after (puerperal sterilization) or at any
time (interval sterilization). Puerperal sterilization performed during the
postpartum hospital stay is a convenient, efﬁcient, and cost-effective
means of preventing future pregnancy.Most sterilization procedures per-
formed in low-resource countries are by mini-laparotomy owing to lack
of equipment, facilities, and expertise in laparoscopic surgery. Laparo-
scopic sterilization can be carried out under local anesthesia, which is
well tolerated. The transcervical route of sterilization is performed either
by hysteroscopic blockage of tubal ostia or by placement of quinacrine hy-
drochloride pellets in the uterine cavity.3.2. Long-term concerns with permanent sterilization
Post-tubal sterilization syndrome and risk of menstrual disturbance
following sterilization have been identiﬁed. The CREST study showed an
association between tubal occlusion and subsequent hysterectomy [8],
but there is no evidence suggesting a higher risk of subsequent men-
strual disorders following tubal sterilization [8]. One study showed a di-
rect association between tubal sterilization and a greater risk ofhospitalization for menstrual disorders, but a biological association
was not supported by the results [9].
Failed sterilizationmay result in ectopic pregnancy and the risk is 7.3
per 1000 procedures for all methods of tubal occlusion [5].
The probability of a woman regretting having undergone sterilization
is estimated to be 14% [5], which may be due to a number of psychoso-
matic factors. The CREST study reported regret following sterilization
among 11 232 women [10,11]. According to this study, regret was more
commonly expressed by women who were sterilized under the age of
30, women of low or nulliparity, and those sterilized immediately after
delivery. Factors that have been identiﬁed that can reliably predict regret
amongwomen include young age at the time of sterilization followed by
subsequent life changes such as divorce and remarriage [12]. Regret was
three timesmore likely amongwomenwho had substantial conﬂict with
their husband prior to tubal sterilization [12].
Request for reversal of sterilization is ﬁve times more likely among
women who have had a conﬂict with their partner or husband prior to
the procedure [12]. Following reversal, successful pregnancy rates will
depend on the age of the woman, the type of tubal occlusion method,
anduse ofmicrosurgery. The successful pregnancy rate following reversal
is approximately 50%, although the rate of successful reanastomosis
varies between 30% and 70% [5].
3.3. Non-contraceptive beneﬁts of permanent methods
Epidemiologic studies have shown that tubal ligation may reduce the
risk of developing ovarian cancer in women with the BRCA1 gene muta-
tion [13]. The underlying mechanism of this is yet to be determined.
Although tubal sterilization does not provide protection from sexu-
ally transmitted infections, tubal occlusion prevents ascending pelvic
infections and therefore reduces hospitalization resulting from pelvic
inﬂammatory disease.
3.4. Failure of permanent methods
A multicenter, prospective cohort study of 10 685 women (CREST)
suggested that the failure rate was related to the method of sterilization
and age of the woman [14]. The failure rate was 1.3% for tubal occlusion
and the highest probability of failure was with the use of spring clips
(36.5 pregnancies in 1000 procedures) [14]. The younger a woman is,
the greater the failure rate; women over the age of 40 have the lowest
failure rate (18.5 in 1000 procedures [14]). The lifetime failure rate for fe-
male sterilization is 1 in 200, with a 10-year failure rate of 2–3 in 1000
procedures [15]. The reasons for failure of sterilization are: incorrect
placement of the mechanical device; development of tuboperitoneal
ﬁstula; spontaneous recanalization of the ends of the fallopian tube;
and unidentiﬁed luteal phase pregnancy.
4. Long-acting reversible contraception (LARC)
LARC methods comprise intrauterine contraception (including cop-
per intrauterine devices and the levonorgestrel intrauterine system),
injectables, and implantable progestogens. LARC methods are the
most effectivemodern contraceptivemethods for preventing unintended
pregnancy. They are long-acting, reliable, safe, cost-effective, andhave ad-
ditional non-contraceptive beneﬁts for a broad range of women seeking
spacing or limiting methods of contraception. LARC methods do not
rely on user adherence and are also suitable for women with medical
disorders.
4.1. Contraceptive prevalence
Globally, 61% of women aged between 15 and 49 years who were
married or in a consensual union used some form of contraception in
2003, with only 9% and 18% using LARC methods in high- and low-
resource countries, respectively [16]. In the UK, 53% of women of
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17% use LARC [17]. Globally, IUDs are used by 14% of women of repro-
ductive age who are married or in union [3]. IUDs are the second most
common method used worldwide, used by 18% of women of reproduc-
tive age in Asia and over 40% in China [3].
4.2. LARC methods
Thesemethods do not depend on compliance or user adherence and
do not require daily attention or use at the time of intercourse; hence,
failure rates are low (b1%) [18].
4.2.1. Copper IUD
This method can provide contraception for up to 10 years. Its effec-
tiveness is dependent on the correct insertion technique. The expulsion
rate is less than 1 in 20 women and is highest within the ﬁrst three
months of insertion and during menstruation [18]. Return of fertility is
immediate after removal of the device. The risk of ectopic pregnancy as-
sociated with IUD use is very low. It can be used as emergency contra-
ception when inserted up to ﬁve days after unprotected intercourse.
4.2.2. Levonorgestrel intrauterine system (LNG-IUS)
This method can provide contraception for up to ﬁve years but it
may continue to be effective for at least seven years in parous women
and for treatment for menorrhagia [19]. Return of fertility is immediate
following removal and 80% of women conceive within 12months of re-
moval. Suppression of proliferation of the endometrium by the LNG-IUS
alters the menstrual bleeding pattern causing marked reduction or
complete cessation of uterine bleeding, which in turn prevents iron de-
ﬁciency anemia [20]. Oligomenorrhea and amenorrhea are frequently
reported with the ﬁrst year of use [20]. Despite the advantages of re-
duced menstrual ﬂow and relief of dysmenorrhea, only 1% of women
who require contraception choose the LNG-IUS [21].
4.2.3. Injectable contraceptives
Two most commonly used injectable contraceptives are depot
medroxyprogesterone acetate (DMPA) and norethindrone enanthate
(NET-EN). Themedian conception time is 8–10months after the last in-
jection of DMPA [22].
4.2.4. Etonogestrel single-rod contraceptive implant
This implant canprovide three years of contraceptive cover. It has high
efﬁcacy [23], low failure rate [24], a high continuation rate, and is cost-
effective [25]. Besides the contraceptive beneﬁts, implants may result in
lighter, less frequent, or absent bleeding. Ovulation resumes rapidly
after removal [26]. The failure rate is lower than most IUDs, LNG-IUS,
and female sterilization [24]. The rate of ectopic pregnancy is low.
4.3. Contraceptive beneﬁts of LARC
The beneﬁts of LARC methods are the limited effort required by the
user tomaintain long- term and effective protection; rapid return to fer-
tility once discontinued; they are safe to use after abortion as well as
after delivery; they are safe during the lactation period; and they are
suitable for women who want an estrogen-free contraceptive method.
4.4. Non-contraceptive beneﬁts of LARC
Copper IUDs have a protective effect against endometrial cancer
[27,28]. The LNG-IUS can be used in women with menorrhagia, with ev-
idence suggesting a reduction in monthly menstrual blood loss of 90% at
1 year and 2%− 4% of women becoming amenorrheic at 1 year [29]. In
addition, evidence suggests a reduction in the size of uterine myomas
by local delivery of levonorgestrel [30]. For women with endometriosis,
use of the LNG-IUS helps reduce pelvic pain and dysmenorrhea [31]. Fur-
thermore, use of the LNG-IUS protects the endometrium against uterinehyperplasia/cancer owing to the progesterone component [32]. Finally,
the release of progestogen from the implant causes ovulation suppression
and thus helps relieve the symptoms of dysmenorrhea [33]. A pilot study
reported that LARCmethods decreased pain scores by 68% when the im-
pact of etonogestrel on endometriosis was studied [34].
4.5. Long-term concerns with LARC
Progesterone-onlymethods can causemenstrual irregularities such as
unscheduled bleeding, prolonged and heavy bleeding, infrequent bleed-
ing, and amenorrhea [35]. In addition, IUDs can cause heavy menstrual
bleeding, dysmenorrhea, pelvic inﬂammatory disease, perforation, expul-
sion, and pain [35]. With injectables there may be irregular bleeding pat-
terns, weight gain, depression, and risk of bone density loss [35].
4.6. Failure rate of LARC methods
With a failure rate of less than 1%, LARC is themost effectivemethod
of reversible contraception.With typical use, the ﬁrst year failure rate of
the copper T 380A is 1%, the LNG-IUS is 0.1%, andwith implants it is 0.1%.
This is similar to permanent methods [36].
5. Counselling on appropriate method of contraception
Counselling by healthcare providers about family planning is essential
to help women make informed choices about the various methods
available and matching their lifestyles and requirements. A multicenter
observational study conducted by the Federation of Obstetric and
Gynaecological Societies of India (FOGSI) evaluated the inﬂuence of struc-
tured contraception counselling on Indian women’s selection of contra-
ceptive methods [37]. The study found that counselling resulted in a
signiﬁcant increase in women opting for modern contraceptive methods.
Poor adherence to contraception is one of the factors contributing to
unintended pregnancies, with an estimated 48% occurring in women
who are using contraception [38]. LARCmethods do not rely on user ad-
herence for effectiveness. In the USA, unintended pregnancy is very
high among sexually active adolescents and women aged 20–24 years
[38]. These women are the right candidates for LARC methods. The
American College of Obstetricians and Gynecologists (ACOG) describes
LARC methods as the ﬁrst-line options for all women and adolescents
on the basis of their top-tier effectiveness, high rates of satisfaction
and continuation, and no need for daily adherence [39]. Adolescents
using LARC methods should also be advised to use condoms to prevent
sexually transmitted infections. The contraceptive CHOICE study in the
USA found thatwhenwomen are counselledwith balanced information
about contraceptive options they choose LARCmethods in preference to
user-dependentmethods such as short-acting reversible contraceptives
[40]. Among women aged 14–49 years, 67% opted for LARC methods
and the 12-month continuation rate was 86% [40].
Counselling about female sterilization should include informationon
other contraceptive options, the probability of later regret having had
the procedure, and also that surgical procedures for reversal are expen-
sive and have a limited success rate.
6. Balance between LARC and permanent methods
Although the global trend shows that more than half of contracep-
tive users relied on female sterilization, use of LARCmethods is increas-
ing. In countries where childbearing begins at a young age, the
dominance of female sterilization indicates a need for transfer to effec-
tive reversible methods. The rate of IUD use increased from 0.8% in
1995 to 5.6% in 2010 [41], but still there is lack of utilization. A review
of global contraceptive trends from2003 to 2012based ondata fromde-
mographic and national surveys shows that intrauterine contraception
use has increased in low-income countries from 27% to 28% and im-
plants and injectables have increased from6% to 9% [42]. The proportion
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age using male or female sterilization fell from 47% to 38% [42].
LARC remains underutilized despite the contraceptive and non-
contraceptive beneﬁts, eligibility for women of any age or parity—
including those who are postpartum or post ﬁrst- or second-trimester
abortion—and women with medical disorders. The reasons for under-
utilization are lack of knowledge among women about LARC, depen-
dence on the provider for information, women’s misconceptions and
misinformation, higher initial cost of the method itself and the place-
ment procedure, and provider bias against the method [40]. Female
sterilization is considered a simple gynecological procedure, but is asso-
ciated with medico-legal issues related to pre-procedure counselling,
surgical complications, and failures.
As LARC methods have similar failure rates and more beneﬁts than
permanent methods, strategies and policies should be adopted to rein-
force their use. Public awareness about LARC methods has increased
their use from 2.4% in 2002 to 5.6% in 2006–2008 [43]. Effective health
professional training programs, addressing the high cost of LARC, and
fully funded family planning programs for users in low-income coun-
tries are a few recommended activities to increase uptake of LARC.Conﬂict of interest
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